News | Sudden Cardiac Arrest | July 28, 2022

Main Line Health, Mayo researchers find natural product may prevent sudden cardiac death from rare inherited syndromes

a team of cardiovascular experts from the Lankenau Institute for Medical Research (LIMR), part of Main Line Health, used experimental models to discover that a natural product found in plants including safflower holds promise for treating a pair of hereditary sudden cardiac death syndromes

getty images


July 28, 2022 — In 2020, a team of cardiovascular experts from the Lankenau Institute for Medical Research (LIMR), part of Main Line Health, used experimental models to discover that a natural product found in plants including safflower holds promise for treating a pair of hereditary sudden cardiac death syndromes

Now, collaborators from LIMR and Mayo Clinic have provided clinical evidence in a new study that acacetin may be the new agent for which cardiologists have been searching. Results were published earlier this month in the journal Circulation: Genomic and Precision Medicine

 “These findings give us optimism that our pioneering work at LIMR will translate into results that save patient lives,” said Charles Antzelevitch, PhD, executive director of LIMR’s Cardiovascular Research Program. “Further studies are clearly warranted to better understand the mechanisms by which acacetin can be beneficial in the treatment of cardiac arrhythmias.” 

Antzelevitch and Mayo’s Michael J. Ackerman, MD, PhD, served as senior authors. ir, PhD, a LIMR research professor, was a coauthor. 

In the study, LIMR and Mayo investigators demonstrated that acacetin exerts its beneficial effects by altering ion channel activity within the cells of the heart. 

Brugada syndrome and early repolarization syndrome fall under the umbrella of J-wave syndromes. They have overlapping cellular and genetic features characterized by irregular heart rhythms. Brugada syndrome affects about 5 of every 10,000 people worldwide. People with it can often die in their sleep. Early repolarization is a common finding in electrocardiograms, but recent studies show the usually benign condition can lead to sudden cardiac death secondary to development of cardiac arrhythmias

J-wave syndromes have been the focus of increasing interest in the cardiology community over the last quarter-century. Antzelevitch and his colleagues have pioneered studies focused on the cellular and genetic basis for these life-threatening syndromes over that period. 

The new study focused on a Brugada syndrome patient with a mutation in the KCND3 gene. Mayo performed testing with induced pluripotent stem cells, which are derived from skin or blood cells that have been reprogrammed to differentiate into cardiomyocytes, cells responsible for the contracting force in the heart. 

Acacetin is a compound distributed in numerous types of plant pigments and is responsible for many of the colors in nature. The research teams believe it may be superior to quinidine, which is one of the current pharmaceutical options for treatment of the J-wave syndromes. 

Acacetin is also considered an attractive therapeutic target to treat inflammatory and immunological disorders. 

For more information: https://www.mainlinehealth.org/ 


Related Content

News | Cardiovascular Clinical Studies

April 20, 2023 — Researchers led by Northwestern University and the University of Texas at Austin (UT) have developed ...

Home April 20, 2023
Home
News | Cardiovascular Clinical Studies

April 5, 2023 — Acarix, a leader in acoustic and AI-based cardiac diagnostics, announced the release of a new study ...

Home April 05, 2023
Home
News | Cardiovascular Clinical Studies

March 29, 2023 — Irregular sleep patterns may play a role in the pathophysiologic development of cardiovascular disease ...

Home March 29, 2023
Home
News | Cardiovascular Clinical Studies

March 27, 2023 — Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing and ...

Home March 27, 2023
Home
News | Cardiovascular Clinical Studies

March 24, 2023 — Vaxxinity, Inc., a Cape Canaveral, FL-based company pioneering the development of a new class of ...

Home March 24, 2023
Home
News | Cardiovascular Clinical Studies

March 22, 2023 — Ancora Heart, Inc., a privately-held Santa Clara, CA-based company developing a completely ...

Home March 22, 2023
Home
News | Cardiovascular Clinical Studies

March 21, 2023 — The first platform to combine real-world cardiology data from millions of people in multiple European ...

Home March 21, 2023
Home
News | Cardiovascular Clinical Studies

March 13, 2023 — BioCardia, Inc., developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2023
Home
News | Cardiovascular Clinical Studies

March 8, 2023 — A unique community-based partnership, the African American Heart Study, will be conducted to measure the ...

Home March 08, 2023
Home
News | Cardiovascular Clinical Studies

March 6, 2023 — A multifaceted intervention to improve prescribing practices increased the likelihood that patients with ...

Home March 06, 2023
Home
Subscribe Now